Gossamer Bio Stock Forecast
NASDAQ: GOSSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 3:03 PM ET
GOSS analyst consensus
Consensus (7 analysts)
buy
Avg. price target
$82.48+749.00%
- Strong buy 1
- Buy 2
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Gossamer Bio (2026-10-09), 3 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $82.48, with a high estimate of $120.00 and a low estimate of $22.40. The average target implies upside of 749.0% from the current price of $9.72.
The spread between the highest and lowest targets is 435.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for GOSS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 2 | 29% |
| Hold | 3 | 43% |
| Sell | 0 | 0% |
| Strong sell | 1 | 14% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $22.40 | +130.57% |
| Average target | $82.48 | +749.00% |
| High target | $120.00 | +1135.20% |